Beyond Hormones: The Non-Hormonal Medical Options for Menopause Symptoms

Understanding Menopause: A Series for Women and the People Who Work With Them, Post 5

More doctors are prescribing hormone therapy, more people are talking about it, and more women feel comfortable trying it than ever before. That does not mean it is the best option for every woman.

It is rarely an all-three-or-nothing decision, either.

Estrogen is the hormone most often ruled out, for a personal or family history of hormone-sensitive breast or endometrial cancer, a history of blood clots, stroke, or heart attack, or active liver disease. Progesterone alone, most often micronized progesterone, is a different calculation: it is sometimes prescribed specifically for hot flashes when estrogen is not an option, though it carries its own, generally smaller set of contraindications, including certain progestin-sensitive cancers and liver disease. Testosterone is separate again: no product is approved for women in Canada, so it is always off-label, almost always for low sexual desire rather than hot flashes, and avoided with liver disease, high cholesterol, or a history of significant acne or hair growth. Some women try one or more of these hormones and simply react badly, reason enough to stop on its own. Others are ruled out of all three from the start. Most are making a more selective, hormone-by-hormone decision, and that nuance rarely makes it into a conversation that treats hormone therapy as one yes-or-no choice. This post is for all of them: the non-hormonal options below have real evidence behind them, and several are newer than most people realize.

Hot Flashes and Night Sweats: The Non-Hormonal Options

Hot flashes and night sweats are not just uncomfortable. Night sweats are one of the biggest drivers of the sleep disruption so many women face in perimenopause and menopause, waking them repeatedly before insomnia even becomes its own problem, which then feeds the mood changes, brain fog, and fatigue covered elsewhere in this series. Getting them under control matters as much for sleep as for comfort.

One new option is a drug class called neurokinin receptor antagonists, which work directly on the brain’s temperature-control centre rather than on hormone levels. Fezolinetant (Veozah) was the first approved by Health Canada, in December 2024; Astellas runs a Canadian patient support program, VEOZAH Connect, to help with reimbursement for those without coverage. Elinzanetant (Lynkuet) followed in July 2025 and is now available through Canadian pharmacies. It blocks two related receptors instead of one, and in clinical trials reduced moderate to severe hot flash frequency by more than 73 percent at 12 weeks, versus 47 percent for placebo. Being so new, it can be hard to find at every pharmacy yet and may not be covered by all insurance.

Older drug classes are still commonly used off-label when a neurokinin antagonist is not accessible or not the right choice for a particular health history. Low-dose SSRIs, including paroxetine, escitalopram, and citalopram, and SNRIs like venlafaxine, can meaningfully reduce hot flash frequency within a few weeks, and help with the anxiety or low mood that often shows up alongside hot flashes. Gabapentin, usually prescribed for nerve pain or seizures, is often used off-label too, particularly for night sweats disrupting sleep, since it is typically taken at bedtime. Clonidine, a blood pressure medication, is used less today, since side effects like dry mouth and dizziness are harder to tolerate than the alternatives above, but it still appears in some treatment plans.

None of this requires giving up on relief without hormone therapy. Cognitive behavioural therapy, in as few as four to six sessions, has moderate to large evidence for reducing both the frequency and distress of hot flashes and night sweats, with no prescription required. Check a private plan’s coverage first, since CBT is not always included and can be costly out of pocket.

Vaginal Dryness and Discomfort: Local Options That Do Not Act on the Whole Body

Vaginal dryness, irritation, and pain during sex, sometimes grouped under genitourinary syndrome of menopause, has its own set of local options. Moisturizers and lubricants are one option and available without a prescription. Vaginal estrogen, the low-dose cream, tablet, applies directly rather than systemically, is the standard of care for these symptoms, and carries a Grade A recommendation for preventing recurrent urinary tract infections in postmenopausal women. Because the dose is so small and stays local, it is often still an option for women who cannot take systemic hormone therapy, though that should always be confirmed with a doctor. Ospemifene (Osphena) is a Health Canada approved oral alternative for women who would rather take a pill than use a local product. Vaginal DHEA (Intrarosa), inserted directly into the vagina, converts locally into small amounts of estrogen and androgen; Health Canada approved it in 2019, and because it acts where it is placed rather than circulating through the bloodstream, it carries a different risk profile than systemic hormone therapy. Vaginal estrogen’s full benefits, including UTI prevention, deserve their own post, coming soon.

Sleep and Mood: The Options, and Why Sleep Deserves to Be Taken Seriously

Chronic sleep loss is not a minor inconvenience. Researchers have compared its long-term toll to smoking.  Poor sleep is linked to higher rates of high blood pressure, heart attack, stroke, and measurable brain changes tied to future cognitive decline. There is also real stigma around treating sleep with medication, as though needing help is a weakness rather than a medical problem like any other. Getting seven to eight hours most nights does as much for long-term heart and brain health as almost anything else here, and for many women that means treating sleep directly rather than waiting it out.

A newer, non-addictive class called dual orexin receptor antagonists, or DORAs, blocks the brain chemical that keeps people awake rather than sedating the whole nervous system like older sleeping pills. Lemborexant (Dayvigo) and daridorexant (Quviviq) are both Health Canada authorized and carry no dependence risk. Other non-addictive options include trazodone, an antidepressant used off label at low dose for sleep, and over-the-counter melatonin. Gabapentin, already mentioned for hot flashes, is also used for its sleep benefit, and cognitive behavioural therapy for insomnia, a structured short-term approach distinct from general talk therapy, has strong evidence for menopause-related sleep problems, though it is not always covered under a private plan either.

For mood symptoms, the same SSRIs and SNRIs used for hot flashes are often the first medical option a doctor raises, since one prescription can address both.

Bone Health: Protecting Against Fracture Without Hormones

Bone loss accelerates sharply once estrogen declines, quietly, often with no symptoms until a fracture forces the issue. Bisphosphonates are the first-line, non-hormonal medication for postmenopausal bone loss in Canada, the standard starting point once a bone density scan shows a problem. Denosumab, a biologic injection given twice a year, is the usual second-line option when bisphosphonates are not tolerated or not enough. Neither treats menopause symptoms directly, but both are worth discussing with a doctor before a fracture forces the issue, not after. Lifestyle factors like calcium, vitamin D, and weight-bearing exercise are covered elsewhere in this series.

Low Sexual Desire: A Non-Hormonal Option Worth Knowing About

Testosterone, discussed earlier, is the option most raised for low sexual desire, but it is always off-label in Canada, since none is approved here for women. Flibanserin (Addyi) is different: Health Canada approved it specifically for postmenopausal women with hypoactive sexual desire disorder in 2021, the only medication approved in Canada for this exact use. It is a once-daily pill working on brain chemistry rather than hormones, and like everything else here, whether it is right depends on individual health history.

Non-Hormonal Options at a Glance

Why This Matters at Work

An employee told that hormone therapy is her only option may simply stop looking for treatment if she cannot or does not want to take it. Knowing a real menu of non-hormonal options exists, several newly approved, changes that conversation. Managers do not need the pharmacology. They need to know treatable does not mean one-size-fits-all, and an employee managing symptoms without hormone therapy is not struggling unnecessarily. She may simply be on a different, equally legitimate path to the same goal.

None of this is medical advice; every option here needs a conversation with a doctor who knows a person’s full health history. What it offers is a starting point: a clear, current picture of what non-hormonal menopause treatment includes, so HRT not being an option never has to mean no option at all.

I am not a doctor. Always talk to your own doctor before starting, stopping, or changing any medication.

If you have questions and want to talk through it, get in touch with Aimee.

—

Aimee Debow is the Founder of Menovate and a certified Menopause Coach. She appeared as a witness before the House of Commons Standing Committee on the Status of Women in June 2026. Menovate helps Canadian organizations build menopause-supportive workplaces through corporate talks, e-learning, and HR advisory services. Learn more at menovate.ca.